{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:38:58Z","timestamp":1776087538297,"version":"3.50.1"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This meta\u2010analysis was performed to compare the safety, efficacy, and pharmacoeconomic of bivalirudin versus heparin in high\u2010risk patients for percutaneous coronary interventions (PCI). Earlier meta\u2010analysis comparing bivalirudin and heparin during PCI demonstrated that bivalirudin caused less bleeding with more stent thrombosis. However, little data were available on the safety of bivalirudin versus heparin in high\u2010risk patients for PCI. Thus, we performed a meta\u2010analysis to evaluate the efficacy and safety in the \u201chigh\u2010risk\u201d patients. A systematic search of electronic databases was conducted up to July 30, 2020. The Cochrane Risk of Bias assessment tool was used to assess the quality of included studies. The primary outcomes were all\u2010cause death and major adverse cardiac events (MACE); secondary outcomes were major and minor bleeding, followed by a cost\u2010minimization analysis comparing bivalirudin and heparin using a local drug and medical costs reported in China. Subgroup analysis was based on the type of disease of the high\u2010risk population. Finally, a total of 10 randomized controlled trials involved 42,699 patients were collected. The Cochrane Risk of Bias Tool was employed to appraise the research quality. No significant difference was noted between bivalirudin and heparin regarding all\u2010cause death and MACE. However, subgroup analysis showed that bivalirudin caused less major bleeding in female (OR:0.65, 95% CI:0.53\u20130.79), diabetes (OR:0.55, 95%CI:0.42\u20130.73), and CKD (OR:0.59, 95%CI:0.63\u20131.65). The scatterers of the included literature were approximately symmetrical, and no research was outside the funnel plot. Additionally, cost\u2010minimization analysis showed that heparin was likely to represent a cost\u2010effective option compared with bivalirudin in China, with potential savings of 2129.53 Chinese Yuan (CNY) per patient for one PCI. Overall, the meta\u2010analysis showed that although bivalirudin appeared to have a lower risk of major bleeding rate, the overall effectiveness and safety between the two groups showed no significant difference in high\u2010risk patients for PCI. But the results of the cost\u2010minimization analysis showed that heparin could be a potential cost\u2010saving drug than bivalirudin in patients for PCI in China.<\/jats:p>","DOI":"10.1002\/prp2.774","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T17:17:46Z","timestamp":1620062266000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A meta\u2010analysis and cost\u2010minimization analysis of bivalirudin versus heparin in high\u2010risk patients for percutaneous coronary intervention"],"prefix":"10.1002","volume":"9","author":[{"given":"Ke\u2010Xin","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacy Xijing Hospital Fourth Military Medical University Xi\u2019an China"},{"name":"School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Xijing Hospital Fourth Military Medical University Xi\u2019an China"},{"name":"School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan\u2010Shan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Xijing Hospital Fourth Military Medical University Xi\u2019an China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen\u2010Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Xijing Hospital Fourth Military Medical University Xi\u2019an China"},{"name":"Department of Pharmacy Shaanxi University of Chinese Medicine Xi'an China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing\u2010Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Xijing Hospital Fourth Military Medical University Xi\u2019an China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-3108","authenticated-orcid":false,"given":"Yi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Xijing Hospital Fourth Military Medical University Xi\u2019an China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-017-0662-1"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5446"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.156"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.18"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2018.01.003"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507854"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311096"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.76"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61216-2"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.140"},{"key":"e_1_2_13_13_1","first-page":"37","article-title":"Gender\u2010related features and quality of life of the patient one year after coronary artery bypass grafting","volume":"93","author":"Sumin AN","year":"2015","journal-title":"Klin Med"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867322666151001122007"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666161205112156"},{"key":"e_1_2_13_16_1","first-page":"e003424","article-title":"Will bivalirudin have an impact in peripheral vascular interventions?","volume":"9","author":"Parikh SA","year":"2016","journal-title":"Circulation"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000767"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-301323"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ancard.2012.10.002"},{"issue":"2","key":"e_1_2_13_20_1","first-page":"76","article-title":"Literature review of pharmacoeconomic on bivalirudin versus heparin treatment in percutaneous coronary intervention patients","volume":"035","author":"Zhu LB","year":"2016","journal-title":"Chin Health Econ"},{"key":"e_1_2_13_21_1","first-page":"S38","article-title":"Cochrane handbook for systematic reviews of interventions version 5.0.1","volume":"5","author":"Higgins JP","year":"2008","journal-title":"Cochrane Collaboration"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.10.029"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV8I11A192"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26407"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.21.2497"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2323"},{"key":"e_1_2_13_28_1","first-page":"214","article-title":"Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography)","author":"Clemmensen P","year":"2015","journal-title":"JACC"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.018"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq008"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31714-8"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2014.10.015"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.09.004"},{"key":"e_1_2_13_34_1","first-page":"e008671","article-title":"Bivalirudin versus heparin monotherapy in elderly patients with myocardial infarction: a prespecified subgroup analysis of the VALIDATE\u2010SWEDEHEART trial","volume":"13","author":"Wester A","year":"2020","journal-title":"Circulation"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcs031"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007204"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.25952"},{"key":"e_1_2_13_38_1","unstructured":"Angiomax (Package Insert) (Bivalirudin) Injection. Parsippany NTMC."},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1255-x"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.06.058"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.05.059"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000134964.01697.C7"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.774","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.774","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:45:09Z","timestamp":1693205109000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/prp2.774"],"URL":"https:\/\/doi.org\/10.1002\/prp2.774","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2021-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00774"}}